Sign In
Buy CDAK
$0.0570
+0 (+0%)
At Close: Jul 03, 2023
CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeut
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors
08:30am, Wednesday, 18'th Aug 2021
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeut
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021
08:30am, Wednesday, 07'th Jul 2021
CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeut
– Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company – – Dr. Sorensen to become CEO of a start-up hemostasis and thrombosis company –
Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference
08:30am, Wednesday, 02'nd Jun 2021
CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeut
Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors
04:05pm, Thursday, 20'th May 2021
– Executive leader with deep regulatory experience bringing innovative biopharmaceutical products from early development to market approval – – Executive leader with deep regulatory experience b
CDAK Stock: Over 30% Increase Intraday Explanation
02:32pm, Thursday, 22'nd Apr 2021
The stock price of Codiak BioSciences Inc (NASDAQ: CDAK) increased by over 30% during intraday trading. This is why it happened.
– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo –
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021
Codiak BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
07:30am, Wednesday, 17'th Mar 2021
– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –
– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract –
Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters' Option
04:30pm, Wednesday, 17'th Feb 2021
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-
Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock
10:18pm, Thursday, 11'th Feb 2021
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-
Codiak Announces Proposed Public Offering of Common Stock
04:17pm, Tuesday, 09'th Feb 2021
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics
– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity
